SYNGENE INTERNATIONAL LTD
Syngene (established in 1993) as a Biocon subsidiary is India’s first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations.
Key Business
- Discovery Services for new drug candidates
- Drug development services from pre-clinical to clinical trials
- Manufacturing services including clinical & commercial supplies
- Dedicated R&D Facilities for clients
Shareholding Pattern
PUBLIC GROUP
PROMOTER GROUP
Financial Summary
| Particulars | March 2024 | March 2023 | March 2022 |
| Sales | 3,489 | 3,193 | 2,604 |
| Sales Growth % | 9.26% | 22.61% | 19.22% |
| Expenses | 2,472 | 2,251 | 1,806 |
| Operating Profit | 1,017 | 942 | 798 |
| OPM % | 29% | 30% | 31% |
| Net Profit | 510 | 464 | 396 |
| EPS in Rs | 12.69 | 11.57 | 9.88 |
Synopsis Of Financials
- Q4 revenue from operations declined by 8% year-on-year.
- Operating EBITDA for the quarter was up 1% to INR317 crores.
- Reported profit after tax was up 6% year-on-year at INR189 crores.
- Full year revenue from operations was INR3,489 crores, up 9% year-on-year.
- Reported profit after tax for the full year was INR519 crores, up 12% from last year.
- Operating EBITDA margin stood at 35% against last year’s 32%.
Final Outlook
Stock is trading at 6.63 times its book value. Company has a low return on equity of 13.4% over last 3 years.
Dividend payout has been low at 10.3% of profits over last 3 years
Promoter holding has decreased over last 3 years: -15.8%
Long term shareholders have made money, with a gain of 17% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering.
SELL is recommended in this situation according to my analysis
Syngene-International-Ltd